SCHEMBL5538554

SCHEMBL5538554

CCOC(=O)CC(=O)N(Cc1ccc(S(C)(=O)=O)cc1)c1cc(Cc2ccc(F)cc2)cnc1C(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.39
CYP2C8 P10632 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
PIK3CA P42336 1/20 0.36
LMNA P02545 4/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA9 Q16790 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545360 0.92 POLB (0.40) CYP2C8CYP2C19PTGDR2MAPTKMT2A
SCHEMBL5546803 0.84 MAPT (0.35) LMNACA1CA2CA4CA9
SCHEMBL5547377 0.83 KDM4E (0.38) LMNAALDH1A1KDM4EMEN1MAPT
SCHEMBL5540690 0.80 MAOB (0.35) LMNAALDH1A1KDM4EMEN1MAPT
SCHEMBL5543021 0.80 MAOB (0.41) LMNAALDH1A1KDM4EMEN1MAPT
SCHEMBL5544805 0.80 RAB9A (0.36) LMNAALDH1A1KDM4EMEN1MAPT
SCHEMBL5538633 0.78 MAOB (0.38) LMNAALDH1A1KDM4EMEN1MAPT
SCHEMBL5540917 0.78 LMNA (0.46) PTGS2CYP2C19LMNAPTGS1
SCHEMBL15163611 0.78 PTGS2 (0.38) PTGS2PIK3CALMNAALDH1A1KDM4E
SCHEMBL4585782 0.78 POLB (0.35) LMNAALDH1A1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 PTGS2 4168/4885CYP2C8 1182/4885CYP2C19 2324/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 PTGS2 4153/4885CYP2C8 2220/4885CYP2C19 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.